Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares saw strong trading volume on Tuesday . 26,087,509 shares were traded during trading, an increase of 16% from the previous session’s volume of 22,576,836 shares.The stock last traded at $11.00 and had previously closed at $10.53.

Analyst Upgrades and Downgrades

Several brokerages have commented on RXRX. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp decreased their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th.

Recursion Pharmaceuticals Stock Performance

The business’s fifty day simple moving average is $7.45 and its 200-day simple moving average is $6.98. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $4.04 billion, a P/E ratio of -6.76 and a beta of 0.86.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of RXRX. Allspring Global Investments Holdings LLC purchased a new position in Recursion Pharmaceuticals in the third quarter worth about $25,000. Decker Retirement Planning Inc. bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $26,000. Private Trust Co. NA bought a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $27,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.